Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCizzle Biotech Regulatory News (CIZ)

Share Price Information for Cizzle Biotech (CIZ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.60
Ask: 1.80
Change: 0.00 (0.00%)
Spread: 0.20 (12.50%)
Open: 1.70
High: 1.70
Low: 1.70
Prev. Close: 1.70
CIZ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Feb 2022 14:51

RNS Number : 5107A
Cizzle Biotechnology Holdings PLC
02 February 2022
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Cizzle Biotechnology Holdings plc

GB00BNG2VN02

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Nirland Limited

City and country of registered office (if applicable)

Guernsey

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

6/12/2021

6. Date on which issuer notified (DD/MM/YYYY):

1/2/2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.99%

0

5.99%

 15,195,532

Position of previous notification (if

applicable)

0

0

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BNG2VN02

15,195,532

5.99%

SUBTOTAL 8. A

15,195,532

5.99%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Based on total issued shares of 253,447,788. The TR1 for Rose Noble Limited showing transaction date 6/12/21 is to be read in conjunction with TR1 for Nirland Limited with same transaction date. The underlying holding has been transferred from Rose Noble Limited to Nirland Limited on 6/12/21 representing an intra-group company transfer resulting in no change in beneficial ownership or change in custodian

 

Place of completion

London

Date of completion

1/2/2022

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUUVSRURUURAR
Date   Source Headline
24th Jun 202412:42 pmRNSResult of AGM
17th Jun 20247:00 amRNSUpdate on North American Strategic Licensing MoU
3rd Jun 20247:00 amRNSNotice of Annual General Meeting
13th May 20247:00 amRNSHolding(s) in Company
30th Apr 20245:00 pmRNSTotal Voting Rights
30th Apr 20249:12 amRNSFinal results for the year ended 31 December 2023
23rd Apr 202411:20 amRNSHolding(s) in Company
2nd Apr 20247:00 amRNSLicensing and Partnership MoU for North America
26th Mar 20247:00 amRNSPlacing to raise £0.62 million
28th Sep 20237:00 amRNSInterim Results
21st Sep 20237:00 amRNSUpdate on Put Option with Conduit
19th Sep 20237:00 amRNSCompletion of Evaluation Programme with Bio-Techne
8th Sep 20237:03 amRNSExtension of and update on Put Option with Conduit
15th Aug 20237:00 amRNSUpdate on Put Option with Conduit
10th Aug 20237:00 amRNSExpansion of Research Agreement and CIZ1B Update
30th Jun 20235:00 pmRNSTotal Voting Rights
28th Jun 202312:01 pmRNSResult of AGM
12th Jun 20232:15 pmRNSTotal Voting Rights
12th Jun 20237:00 amRNSSubscription to raise £350,000
5th Jun 202312:35 pmRNSPosting of Annual Report and Notice of AGM
15th May 20231:42 pmRNSUpdate on Royalty Sharing Agreement in AZD1656
27th Apr 20237:00 amRNSResults for the year ended 31 December 2022
24th Apr 20237:00 amRNSNew Research Agreement with the University of York
30th Mar 202311:05 amRNSSecond Price Monitoring Extn
30th Mar 202311:00 amRNSPrice Monitoring Extension
17th Mar 20234:35 pmRNSPrice Monitoring Extension
13th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSIssue of Options in lieu of salary increases
22nd Feb 20237:52 amRNSHolding(s) in Company
6th Feb 20237:02 amRNSHolding(s) in Company
31st Jan 20235:00 pmRNSTotal Voting Rights
24th Jan 202312:48 pmRNSHolding(s) in Company
20th Dec 20223:17 pmRNSUpdate re. timing of Admission
19th Dec 20227:00 amRNSPut Option re AZD1656 & £115,586 Subscription
23rd Nov 20228:04 amRNSClinical Study for Lung Cancer Detection in China
9th Nov 20227:00 amRNSConduit Pharmaceuticals Proposed Listing
31st Oct 20225:00 pmRNSTotal Voting Rights
4th Oct 20228:00 amRNSAdmission and Total Voting Rights
30th Sep 20225:00 pmRNSTotal Voting Rights
29th Sep 20223:49 pmRNSIssue of Consideration Shares & Option Exercise
28th Sep 20223:05 pmRNSHolding(s) in Company
28th Sep 20227:00 amRNSInterim results
26th Sep 20228:00 amRNSAdmission and Total Voting Rights
21st Sep 202211:23 amRNSSubscription, Facility & Publication of Prospectus
18th Aug 20229:21 amRNSArcadia Clinical Trial Results Published
10th Aug 20224:41 pmRNSSecond Price Monitoring Extn
10th Aug 20224:36 pmRNSPrice Monitoring Extension
11th Jul 20227:15 amEQSHardman & Co Research: Cizzle Biotechnology (CIZ): Considerable progress in first year since listing
5th Jul 20227:00 amRNSUpdate on Development of Proprietary Antibodies
27th Jun 202211:52 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.